 |
|
|
| |
All-Oral Therapy With Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment-Experienced Genotype 2/3 HCV-Infected Patients:
Results of the Phase 3 FUSION Trial
|
| |
| |
Reported by Jules Levin APASL 2013 June 6-10 Singapore
Stuart Gordon7, Jordan Feld1, David Nelson2, Kris V. Kowdley3, M. Tarek Al-Assi4, Ming Lin5, Hongmei Mo5, John McNally5, Diana M. Brainard5, William T. Symonds5, John G. McHutchison5, Keyur Patel6
7Henry Ford Health Systems, Detroit, MI, USA; 1University of Toronto, Ontario, Canada; 2University of Florida, Gainesville, FL, USA; 3Digestive Disease Institute, Virginia Mason Medical Center, Seattle, WA, USA; 4Texas Digestive Disease Consultants, Arlington, TX, USA; 5Gilead Sciences, Inc., Foster City, CA, USA; 6Duke University, Durham, NC, USA
NEJM 4/2013: Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
http://www.natap.org/2013/EASL/EASL_08.htm
|
| |
|
|
|
|
|
